Image
Elizabeth Horn
Dr. S. Nabeel Hyder presented “SGLT2-‘Eyes’ on the Reno-Protection Prize: Reduction of Post-PCI Contrast-Associated AKI in Diabetic Patients Using SGLT2 Inhibitors” during the ESC Congress 2024 held August 30th to September 2nd in London.
Patients with diabetes have a higher risk of developing coronary artery disease and kidney complications. Sodium-glucose co-transporter inhibitors (SGLT2i) are known to be beneficial in reducing cardiovascular risk in patients with diabetes and coronary artery disease. There is growing evidence to show that SGLT2i may also be helpful in reducing kidney complications. However, this was previously only replicated when reviewing the data of small groups of patients.
Dr. Hyder and his co-authors reviewed the BMC2 PCI registry data of nearly 20,000 PCI procedure patients with diabetes and taking SGLT2i to determine if the medication may help prevent contrast-associated acute kidney injury (CA-AKI). They found that patients with diabetes taking SGLT2i prior to stent placement procedures had significantly fewer procedure-related kidney complications than patients with diabetes not taking these medications.
“We strive to make minimally invasive coronary stent implantation procedures even safer for patients with coronary artery disease,” Dr. Hyder said. “SGLT2i are an increasingly common medication used for patients with heart disease and/or diabetes – our findings importantly suggest that these medications may have additive benefits in reducing kidney complications related to stent implantation procedures.”
The results should encourage further investigation into the beneficial effects of SGLT2i in reducing the risk of CA-AKI.
Additional authors are Milan Seth, MS; David E. Hamilton, MD; Joseph Chattahi, MD; Vishal Gupta, MD, MPH; Carlo Briguori, MD, PhD, FSCAI; Michael Rudnick, MD; Devraj Sukul, MD, MSc, FACC, FSCAI; and Hitinder S. Gurm, MD.